| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 70095-0080-01 | 70095-0080 | ERIBULIN MESYLATE | ERIBULIN MESYLATE | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | May 15, 2025 | In Use | |
| 00015-3072-97 | 00015-3072 | Cisplatin | Platinol | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 1, 2005 | Jun 15, 2014 | No Longer Used | |
| 81927-0106-01 | 81927-0106 | Thiotepa | TEPYLUTE | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intravenous | Mar 31, 2025 | In Use | |
| 50419-0171-03 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
| 71288-0133-01 | 71288-0133 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 13, 2025 | In Use | |
| 70710-1525-09 | 70710-1525 | Carmustine | Carmustine | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Dec 24, 2020 | In Use | ||
| 53150-0336-01 | 53150-0336 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 5.0 mg/5mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Apr 30, 2013 | Dec 31, 2016 | No Longer Used |
| 70518-0223-02 | 70518-0223 | METHOTREXATE | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb 17, 2017 | Oct 22, 2019 | No Longer Used |
| 00409-1700-01 | 00409-1700 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Jul 27, 2022 | In Use | |
| 69097-0030-08 | 69097-0030 | Nilotinib | Nilotinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 18, 2025 | In Use | |
| 00069-0155-01 | 00069-0155 | Cytarabine | Cytarabine | 2.0 g/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Jan 31, 2012 | Dec 31, 2017 | No Longer Used |
| 00078-0620-61 | 00078-0620 | Everolimus | Afinitor | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jul 29, 2011 | In Use | |
| 00078-0592-87 | 00078-0592 | Nilotinib | Tasigna | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 29, 2007 | In Use | |
| 60505-6277-00 | 60505-6277 | CISplatin | CISplatin | 50.0 mg/50mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 6, 2023 | In Use | |
| 81864-0101-30 | 81864-0101 | Momelotinib | Ojjaara | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sep 15, 2023 | In Use | |
| 00078-0567-61 | 00078-0567 | Everolimus | Afinitor | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 22, 2010 | In Use | |
| 00409-0201-02 | 00409-0201 | DOCETAXEL ANHYDROUS | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 17, 2011 | In Use | |
| 72338-0100-01 | 72338-0100 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jun 4, 2018 | In Use | |
| 83090-0009-10 | 83090-0009 | Arsenic trioxide | ARSENIC TRIOXIDE | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Nov 9, 2023 | In Use | |
| 83090-0010-10 | 83090-0010 | Arsenic trioxide | ARSENIC TRIOXIDE | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Nov 9, 2023 | In Use | |
| 63323-0117-28 | 63323-0117 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 12, 2000 | In Use | |
| 70710-1655-01 | 70710-1655 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 26, 2022 | In Use | |
| 76282-0788-12 | 76282-0788 | Nilotinib | Nilotinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 14, 2025 | In Use | |
| 59137-0335-01 | 59137-0335 | Treosulfan | GRAFAPEX | 1000.0 mg/g | Chemotherapy | Alkylating Agent | Alkyl Sulfonate | Intravenous | Jan 28, 2025 | In Use | |
| 68727-0745-01 | 68727-0745 | (daunorubicin and cytarabine) liposome | Vyxeos | 100.0 mg/20mL, 44.0 mg/20mL | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | Intravenous | Aug 3, 2017 | In Use |
Found 12250 results — Export these results
Home